Heparin versus Saline Solution for Locking of Totally Implantable Venous Access Port (TIVAP): Cohort Study of the First Kurdistan Series of TIVAP

Baram, Aram; Majeed, Goran; Abdullah, Hazha; Subhi, Allaa

doi:10.4236/alc.2014.34010

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Document all routine and extraordinary management actions on the CVAD for correct monitoring. 102,103 (A)…”

Section: Recommendations For External Cvadsmentioning

confidence: 99%

“…Use 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin antisepsis before inserting the non-coring Huber needle respecting the time of action. [102][103][104] 2. Flush the port preferably orienting the bevel of the Huber needle in the opposite direction from the connection between the catheter and the reservoir, so to facilitate the removal of deposits.…”

Section: Recommendations For Totally Implantable Cvads (Ports)mentioning

confidence: 99%

“…Furthermore, prospective randomized controlled trials showed that the use of heparinized solutions had no significant advantage compared to normal saline in the reduction of catheter malfunction due to clots. 102,105,106,108,109 7. Replace the dressing every 7 days or at each replacement of the Huber needle.…”

Section: (B Iii)mentioning

confidence: 99%

“…The recent literature shows 102,106,108,109,126,127 that maintaining the patency of a CVAD does not require the use of heparin but the adoption of strategies such as (a) an adequate protocol for rinsing the device (FLUSH) and closing it (LOCK) with normal saline, and (b) the adoption of NFC able to prevent blood reflux (backflow) inside the catheter at the time of disconnection from the venous line (Neutral displacement NFC).…”

Section: Choice Of Securement Devicesmentioning

confidence: 99%

See 3 more Smart Citations

Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease

et al. 2020

View full text Add to dashboard Cite

Introduction: Central venous accesses devices (CVADs) have a fundamental importance for diagnostic and therapeutic purposes in pediatric onco-hematological patients. The treatment of pediatric onco-hematological diseases is complex and requires the use of integrated multimodal therapies. Long-lasting and safe central venous access is therefore a cornerstone for any successful treatment. Methods: The aim of this work is to define pediatric guidelines about the management of CVADs in onco-hematology. A panel of experts belonging to the working groups on Infections and Supportive Therapy, Surgery and Nursing of the Italian Pediatric Hematology Oncology Association (AIEOP) revised the scientific literature systematically, scored the level of evidence and prepared these guidelines. The content of the following guidelines was approved by the Scientific Board of AIEOP. Results and Conclusions: Important innovations have been developed recently in the field of CVADs, leading to new insertion methods, new materials and new strategy in the overall management of the device, especially in the adult population. These guidelines recommend how to apply these innovations in the pediatric population, and are directed to all physicians, nurses and health personnel active in the daily management of CVADs. Their aim is to update the knowledge on CVAD and improve the standard of care in pediatric patients with malignancies.

show abstract

“…Document all routine and extraordinary management actions on the CVAD for correct monitoring. 102,103 (A)…”

Section: Recommendations For External Cvadsmentioning

confidence: 99%

Section: Recommendations For Totally Implantable Cvads (Ports)mentioning

confidence: 99%

Section: (B Iii)mentioning

confidence: 99%

Section: Choice Of Securement Devicesmentioning

confidence: 99%

See 2 more Smart Citations

Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease

et al. 2020

View full text Add to dashboard Cite

show abstract

Dosage of heparin for patency of the totally implanted central venous catheter in cancer patients

Oliveira

Rodrigues

Ramos

et al. 2020

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Objective: to analyze the evidence available in the literature about the lowest necessary dose of heparin to maintain the patency of the totally implanted central venous catheter in adult cancer patients. Method: an integrative literature review, carried out in the following databases: Literatura Latino-Americana e do Caribe em Ciências de Saúde, Sciverse Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, including thirteen studies. Results: the evidence showed that the dose of heparin (300 IU/ml) is the most used in maintaining the patency of the totally implanted central venous catheter. Conclusion: according to the selected studies, the lowest dose of heparin found in maintaining the patency of the totally implanted central venous catheter in cancer patients was 10 UN/ml with a volume of 5 ml of the heparin solution.

show abstract

Locking of venous port systems in breaks between infusion cycles: heparinized or normal saline?

Gumeniuk¹

2019

View full text Add to dashboard Cite

встуП. Протягом багатьох років стандартною практикою для промивання й замикання імплантованих венозних порт-систем (портів) вважалося використання гепаринізованого фізіологічного розчину, хоча цей підхід не має жодних обґрунтувань. Як альтернативу гепариновому розчину можна використовувати звичайний розчин хлориду натрію. Матеріали і Методи. Проведено аналіз джерел літератури-практичних рекомендацій із догляду за порт-системами, наукових статей і клінічних досліджень, присвячених вивченню порівняльної ефективності й безпеки застосування гепаринізованого та звичайного фізіологічного розчину для замикання порт-систем у дорослих пацієнтів. реЗулЬтати. Тривале застосування навіть низьких доз гепарину може зумовити виникнення кровотеч і тромбоцитопенії, особливо в пацієнтів, які перебувають на діалізі, та онкологічних хворих, що може призводити до тяжких або таких, що загрожують життю, ускладнень. Використання гепарину пов'язане з помилками в дозуванні, формуванням біоплівок S. aureus, несумісністю з іншими лікарськими препаратами. Результати ретроспективних і рандомізованих проспективних досліджень свідчать, що застосування звичайного фізіо логічного розчину для замикання порт-систем є ефективним і безпечним та не асоціюється з підвищеним ризиком ускладнень. висновки. У дорослих пацієнтів різного профілю (зі злоякісними новоутвореннями й іншою патологією) застосування звичайного розчину NaCl для замикання імплантованих венозних портів замість гепаринізованого розчину є ефективним і безпечним. Відмова від гепарину виключає ризики, пов'язані з його застосуванням, зберігає час і кошти для медичного персоналу та пацієнтів.

show abstract

Heparin versus Saline Solution for Locking of Totally Implantable Venous Access Port (TIVAP): Cohort Study of the First Kurdistan Series of TIVAP

Cited by 4 publications

References 22 publications

Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease

Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease

Dosage of heparin for patency of the totally implanted central venous catheter in cancer patients

Locking of venous port systems in breaks between infusion cycles: heparinized or normal saline?

Contact Info

Product

Resources

About